Horizon Discovery (Horizon) has announced the formation of a partnership with Caliper Discovery Alliances and Services, (CDAS) that expands the oncology cell line and screening capabilities of CDAS for testing single drugs and combination therapies.
Through this alliance, CDAS is now able to offers, genetically-defined, and isogenic human cancer cell lines that allow researchers to better identify and characterize personalized drugs targeted at a specific subset of patients.
The alliance with Horizon Discovery adds significant value to existing CDAS offerings and illustrates Caliper’s commitment to providing accurate in vitro and in vivo models for oncology research,” said David Manyak, Executive Vice President of Drug Discovery Services, Caliper Life Sciences.
"The addition of Horizon’s isogenic cell lines to our existing oncology cell proliferation panel, and the ability to correlate results from these isogenic cell lines to efficacy in specific patient populations, further solidifies Caliper’s in vitro-in vivo-human (IIH) bridge.”
The new offering is available now on standard Caliper commercial terms.